Impact Biomedicines v. Teva: Myelofibrosis Patent Consent Judgment
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Impact Biomedicines, Inc. v. Teva Pharmaceutical Industries, Ltd. |
| Case Number | 2:23-cv-21385 |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Oct 2023 – Mar 2024 147 days |
| Outcome | Plaintiff Win — Consent Judgment |
| Patents at Issue | |
| Accused Products | Teva’s proposed generic pharmaceutical formulation |
Case Overview
The Parties
⚖️ Plaintiff
Biopharmaceutical company focused on developing therapies for hematologic malignancies, with patents covering fedratinib (a JAK2 inhibitor).
🛡️ Defendant
One of the world’s largest generic drug manufacturers, frequently involved in Paragraph IV / Hatch-Waxman litigation.
Patents at Issue
This case centered on two U.S. patents protecting compositions and treatment methods for myelofibrosis and myeloproliferative disorders. Both patents protect formulation and method-of-treatment claims in the JAK inhibitor therapeutic space.
- • U.S. Patent No. 10,391,094 B2 — compositions and methods for treating myelofibrosis
- • U.S. Patent No. 11,400,092 B2 — methods of treating myeloproliferative disorders
Developing a generic drug?
Check if your formulation might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome: Consent Judgment
The case terminated by **consent judgment** — a court-entered order reflecting the mutual agreement of both parties. The specific damages amount and any licensing terms embedded in the resolution were not publicly disclosed, which is common in pharmaceutical patent consent judgments where commercial licensing arrangements accompany judicial resolution.
Key Legal Issues
The case proceeded as a straightforward **infringement action** under the Hatch-Waxman framework. The early resolution suggests that parties assessed the strength of infringement positions, validity challenges, and litigation risk, determining that a negotiated resolution served their commercial interests more efficiently than protracted litigation. This outcome reflects meaningful dynamics in pharmaceutical patent litigation, including the strategic calculus of Hatch-Waxman and the strength of layered patent portfolios covering both compositions and methods of treatment.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in specialty pharma. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in this therapeutic space
- See which companies are most active in pharma IP
- Understand ANDA litigation patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic formulation.
- Input your formulation details or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
JAK inhibitor formulations
2 Patents Asserted
Both composition & method-of-treatment
Early Resolution
Signals strong patent position
✅ Key Takeaways
Consent judgments in Hatch-Waxman cases can deliver enforceable market exclusivity protections without claim construction risk.
Search related case law →Dual assertion of composition and method-of-treatment patents amplifies infringement exposure and settlement leverage.
Explore precedents →Frequently Asked Questions
Two patents: U.S. Patent No. 10,391,094 B2 (compositions and methods for treating myelofibrosis) and U.S. Patent No. 11,400,092 B2 (methods of treating myeloproliferative disorders).
The parties reached a mutual agreement resolving the infringement action. Specific terms were not publicly disclosed, consistent with common practice in Hatch-Waxman pharmaceutical consent judgments.
The intact patent status following consent judgment signals ongoing IP barriers to generic market entry, informing litigation posture for other ANDA filers referencing the same therapeutic.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of New Jersey — Case No. 2:23-cv-21385
- USPTO Patent Full-Text Database — US10391094B2
- Hatch-Waxman Litigation Overview — USPTO
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.